MicroPort CardioFlow Medtech Corporation

Informe acción SEHK:2160

Capitalización de mercado: HK$1.7b

MicroPort CardioFlow Medtech Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de MicroPort CardioFlow Medtech han disminuido a una tasa media anual de -15.7%, mientras que en la industria Medical Equipment los beneficios crecieron en un 14.7% anualmente. Los ingresos han ido creciendo a una tasa media de 27.3% al año.

Información clave

-15.7%

Tasa de crecimiento de los beneficios

-8.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment 13.7%
Tasa de crecimiento de los ingresos27.3%
Rentabilidad financiera-15.9%
Margen neto-91.0%
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

Sep 27
MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Sep 27
After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Aug 07
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

Jun 19
Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

May 29
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

Apr 05
MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Feb 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Jan 18
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Oct 04
Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

May 31
Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

May 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

Apr 06
The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

Feb 08
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Oct 18
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Jun 30
We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

Apr 04
Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 03
MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Jan 21
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

Sep 05
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Jun 07
We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

May 03
Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

Desglose de ingresos y gastos

Cómo gana y gasta dinero MicroPort CardioFlow Medtech. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SEHK:2160 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 24383-349297211
31 Mar 24360-410295224
31 Dec 23336-472293237
30 Sep 23319-491273246
30 Jun 23303-511253254
31 Mar 23277-483243239
31 Dec 22251-454233224
30 Sep 22245-345213203
30 Jun 22239-236193182
31 Mar 22220-209173166
31 Dec 21201-183152151
30 Sep 21176-265131133
30 Jun 21151-346111116
31 Mar 21128-372104106
31 Dec 20104-3989797
31 Dec 1922-1453797

Ingresos de calidad: 2160 actualmente no es rentable.

Margen de beneficios creciente: 2160 actualmente no es rentable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 2160 no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 15.7% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 2160 en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 2160 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (-4.3%).


Rentabilidad financiera

Alta ROE: 2160 tiene una rentabilidad financiera negativa (-15.92%), ya que actualmente no es rentable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado